Polaryx Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• PLX-200 · Oncology
  PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Polaryx Therapeutics, Inc. portfolio CI brief
• Polaryx Therapeutics, Inc. pipeline updates RSS